What is it about?
The study is a comparison in terms of patient survival gain for two therapeutic approaches: Immunotherapy using dendritic cells versus a more classical approach using Bevacizumab alongside Irinotecan.
Featured Image
Read the Original
This page is a summary of: Dendritic cell immunotherapy versus bevacizumab plus irinotecan in recurrent malignant glioma patients: a survival gain analysis, OncoTargets and Therapy, November 2016, Dove Medical Press,
DOI: 10.2147/ott.s112842.
You can read the full text:
Contributors
The following have contributed to this page
